# The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension

> **NCT07013149** · — · RECRUITING · sponsor: **University of Sao Paulo General Hospital** · enrollment: 121 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

## Interventions

- **OTHER:** Switch from Ambrisentan to Bosentan

## Key facts

- **NCT ID:** NCT07013149
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 121 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013149, "The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07013149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*